Lincoln Pharmaceuticals Limited (BOM:531633)

Market Cap	11.83B +8.2%
Revenue (ttm)	6.94B +10.2%
Net Income	964.53M +11.7%
EPS	48.15 +11.7%
Shares Out	20.03M
PE Ratio	12.26
Forward PE	n/a
Dividend	1.80 (0.30%)
Ex-Dividend Date	Sep 11, 2026

Volume	2,685
Open	596.00
Previous Close	595.60
Day's Range	587.50 - 601.70
52-Week Range	439.95 - 770.00
Beta	0.39
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, anti-infective, anti-bacterial, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics in the form of tablets, capsules, injectables, dry syrups, sprays, ointments etc. It exports its produc...

• Industry: Pharmaceutical Preparations
• Founded: 1979
• Employees: 1,352
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531633

Financial Performance

In fiscal year 2026, Lincoln Pharmaceuticals's revenue was 6.71 billion, an increase of 7.67% compared to the previous year's 6.23 billion. Earnings were 878.94 million, an increase of 6.74%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 27, 2026

Data Sources Report a data error